EGLT Egalet Corporation

-0.06  -4%
Previous Close 1.52
Open 1.54
Price To book -1.62
Market Cap 62850613
Shares 43,048,365
Volume 367,850
Short Ratio 10.26
Av. Daily Volume 484,378

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL announced June 20, 2017.
Acute and chronic moderate to severe pain
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
Moderate to severe chronic pain
Approved January 9, 2017.
Egalet-001 (ARYMO ER)
Abuse-Deterrent Morphine

Latest News

  1. National Lacrosse League and Egalet Corporation Announce Educational Partnership Around A Non-Narcotic Pain Option and Responsible Pain Management
  2. Egalet Presented New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse
  3. Egalet to Present at Investor Conferences this Fall
  4. Egalet's Partner Ascend Therapeutics® U.S., LLC Begins Promotion of SPRIX® Nasal Spray
  5. Edited Transcript of EGLT earnings conference call or presentation 9-Aug-17 8:30pm GMT
  6. Egalet reports 2Q loss
  7. Egalet trims non-sales workforce by 40%
  8. Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan
  9. Investor Network: Egalet Corporation to Host Earnings Call
  10. Egalet to Host Conference Call and Webcast on August 9, 2017 to Discuss Second Quarter 2017 Financial Results
  11. Egalet Announces Closing of $30 Million Public Equity Offering
  12. Egalet Announces Pricing of Public Offering of Common Stock and Warrants
  13. 3 Stocks to Watch on Thursday: Egalet Corp (EGLT), Herman Miller, Inc. (MLHR) and PriceSmart, Inc. (PSMT)
  14. Egalet's stock plunges toward record low after stock offering plan
  15. Egalet Announces Proposed Public Offering of Common Stock and Warrants
  16. Egalet Stumbles Over FDA Complete Response Letter
  17. Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO
  18. ETFs with exposure to Egalet Corp. : June 8, 2017
  19. Today's Research Reports on Stocks to Watch: Egalet Corporation and 22nd Century Group
  20. Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray

SEC Filings

  1. 8-K - Current report 171018060
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017819
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 17967936
  4. 8-K - Current report 17960233
  5. 8-K/A [Amend] - Current report 17955497
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17955422
  7. 8-K - Current report 17953165
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17949390
  9. 8-K - Current report 17948155
  10. 8-K - Current report 17919941